A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 26, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Presbyopia
Interventions
DRUG

AGN-199201 ophthalmic solution

1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-190584 ophthalmic solution

1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-199201 Vehicle

Vehicle to AGN-199201

DRUG

AGN-190584 Vehicle

Vehicle to AGN-190584

Trial Locations (25)

16066

Scott & Christie and Associates, PC, Cranberry Township

21210

Specialized Eye Care, Baltimore

27101

James D. Branch, Winston-Salem

29425

Medical University of South Carolina, Charleston

30260

Clayton Eye Center, Morrow

33143

MedEye Associates, Miami

34239

Center for Sight, Sarasota

34474

Central Florida Eye Institute, Ocala

38119

Total Eye Care, PA, Memphis

40206

Silverstein Eye Centers, Louisville

The Eye Care Institute, Louisville

77555

University of Texas Medical Branch, Galveston

78229

R and R Eye Research, LLC, San Antonio

78240

Medical Center Ophthalmology Associates, San Antonio

79902

Cataract and Glaucoma Center, El Paso

84020

Hoopes Durrie Rivera Research, LLC, Draper

90505

Wolstan and Golberg Eye Associates, Torrance

90630

WCCT Global, LLC, Cypress

90701

Sall Research Medical Center, Artesia

91007

Retina Institute of California Medical Group, Arcadia

91203

Specialty Eye Care Medical Center, Glendale

91204

Lugene Eye Institute, Glendale

92663

The Eye Research Foundation, Newport Beach

94303

Stanford Eye and Laser Center, Palo Alto

97210

Devers Eye Institute, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY